恩威医药
(301331)
| 流通市值：7.26亿 | | | 总市值：23.86亿 |
| 流通股本：3128.62万 | | | 总股本：1.03亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 366,010,905.68 | 453,622,367.33 | 221,123,205.57 | 236,120,514.71 |
| 应收票据及应收账款 | 104,098,324.83 | 115,623,174.07 | 97,802,419.1 | 93,095,689.67 |
| 应收账款 | 104,098,324.83 | 115,623,174.07 | 97,802,419.1 | 93,095,689.67 |
| 应收款项融资 | 122,812,093.88 | 98,773,030.37 | 179,348,477.51 | 171,900,424.39 |
| 预付款项 | 25,311,174.63 | 14,112,034.68 | 12,240,213.93 | 14,911,422.66 |
| 其他应收款合计 | 5,652,462.64 | 4,695,988.32 | 4,422,757.56 | 3,987,706.52 |
| 存货 | 107,488,765.03 | 127,727,285.78 | 127,608,315.47 | 107,367,067.33 |
| 其他流动资产 | 3,518,333.58 | 1,804,484.9 | 3,435,816.89 | 2,316,777.34 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 864,538,310.27 | 916,330,278.24 | 796,383,809.55 | 786,859,452.41 |
| 非流动资产: | | | | |
| 长期股权投资 | 330,447.34 | 380,006.03 | 373,989.35 | 373,989.35 |
| 投资性房地产 | 29,075,406.65 | 29,674,642.7 | 30,273,878.75 | 30,873,114.8 |
| 固定资产 | 209,539,965.27 | 210,943,934.92 | 216,489,627.12 | 220,638,376.27 |
| 在建工程 | 35,605,470.48 | 21,291,143.43 | 20,866,684.5 | 8,818,254.75 |
| 使用权资产 | 2,112,921.03 | 1,660,093.84 | 1,992,112.6 | 1,668,083.21 |
| 无形资产 | 137,396,425.04 | 139,987,487.54 | 144,015,648.53 | 148,043,809.24 |
| 商誉 | 100,552,610.87 | 100,552,610.87 | 100,552,610.87 | 100,552,610.87 |
| 长期待摊费用 | 7,311,330.6 | 8,659,188.84 | 10,077,857.34 | 10,682,332.13 |
| 递延所得税资产 | 6,483,749.38 | 5,661,498.53 | 4,176,035.88 | 3,047,439.1 |
| 其他非流动资产 | 29,947,914.8 | 36,185,037.8 | 30,335,117.8 | 25,940,217.8 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 558,356,241.46 | 554,995,644.5 | 559,153,562.74 | 550,638,227.52 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,422,894,551.73 | 1,471,325,922.74 | 1,355,537,372.29 | 1,337,497,679.93 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 30,387,324.73 | 44,640,038.51 | 48,544,704.66 | 30,940,833.63 |
| 应付账款 | 30,387,324.73 | 44,640,038.51 | 48,544,704.66 | 30,940,833.63 |
| 合同负债 | 17,670,831.76 | 19,942,022.17 | 21,599,387.56 | 14,009,811.41 |
| 应付职工薪酬 | 30,305,022.79 | 32,609,290.05 | 33,538,642.2 | 39,942,277.75 |
| 应交税费 | 11,844,093.36 | 14,396,435.37 | 11,131,110.35 | 17,313,965.77 |
| 其他应付款合计 | 84,175,658.86 | 99,347,070.3 | 100,259,696.87 | 104,862,634.13 |
| 一年内到期的非流动负债 | 1,344,118.8 | 1,298,079.24 | 1,284,619.36 | 882,307.48 |
| 其他流动负债 | 2,297,208.13 | 2,592,462.87 | 2,807,920.39 | 1,821,275.49 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 178,024,258.43 | 214,825,398.51 | 219,166,081.39 | 209,773,105.66 |
| 非流动负债: | | | | |
| 长期借款 | 200,000,000 | 220,000,000 | 33,000,000 | - |
| 租赁负债 | 617,197.82 | - | - | 455,192.28 |
| 递延收益 | 10,211,263.25 | 10,779,186.08 | 11,347,108.91 | 11,915,031.74 |
| 递延所得税负债 | 12,077,693.94 | 12,160,760.83 | 12,472,198.62 | 12,168,443.84 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 222,906,155.01 | 242,939,946.91 | 56,819,307.53 | 24,538,667.86 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 400,930,413.44 | 457,765,345.42 | 275,985,388.92 | 234,311,773.52 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 102,891,887 | 102,891,887 | 70,138,359 | 70,138,359 |
| 资本公积 | 661,056,632.87 | 654,540,897.79 | 679,401,313.29 | 671,508,200.79 |
| 减:库存股 | 101,753,887.68 | 99,554,193.72 | 70,733,876.51 | 30,782,910.98 |
| 盈余公积 | 35,069,179.5 | 35,069,179.5 | 35,069,179.5 | 35,069,179.5 |
| 未分配利润 | 324,700,326.6 | 320,612,806.75 | 365,677,008.09 | 357,253,078.1 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 1,021,964,138.29 | 1,013,560,577.32 | 1,079,551,983.37 | 1,103,185,906.41 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 1,021,964,138.29 | 1,013,560,577.32 | 1,079,551,983.37 | 1,103,185,906.41 |
| 负债和股东权益合计 | 1,422,894,551.73 | 1,471,325,922.74 | 1,355,537,372.29 | 1,337,497,679.93 |
| 公告日期 | 2024-10-24 | 2024-08-30 | 2024-04-22 | 2024-04-22 |
| 审计意见(境内) | | | | 标准无保留意见 |